Effects of Losartan on Angiotensin and Bradykinin Peptides and Angiotensin-Converting Enzyme
The DOI matches its Crossref record.
Abstract
Antagonists of the type 1 (AT1) angiotensin II (Ang II) receptor increase renin secretion and plasma Ang II levels, and the increased Ang II levels may counteract the effects of the antagonist. Moreover, other investigators have suggested that the reactive increase in Ang II levels may increase bradykinin (BK) levels through stimulation of the type 2 Ang II receptor (AT2). We investigated the acute effects of the AT1 receptor antagonist losartan (intraarterial injection of 10 mg/kg every 12 h) in male Sprague Dawley rats by measuring circulating angiotensin and BK peptides at 6, 12, and 24 h. Whereas acute losartan administration increased blood angiotensin levels four- to sixfold, blood BK levels were unchanged. We also investigated the effects of losartan administered for 8 days (10 mg/kg every 12 hours, by intraperitoneal injection) on circulating and tissue levels of angiotensin and BK peptides, and angiotensin-converting enzyme (ACE). Losartan increased plasma renin levels 100-fold; plasma angiotensinogen levels decreased to 24% of control; and plasma aldosterone levels were unchanged. Ang II levels in plasma, adrenal, lung, heart, and aorta were increased 25-, 8-, 3.5-, 2.4-, and 14-fold, respectively, by losartan administration. By contrast, kidney Ang II levels decreased to 71% of control, accompanied by a decrease in kidney levels of BK-(1-7) and BK-(1-9). No other tissue showed a change in BK peptide levels, except for a reduction in blood levels of BK-(1-8) to 43% of control. Plasma ACE increased by 13-50%, but tissue ACE levels were unchanged. These data demonstrate that losartan has tissue-specific effects on endogenous levels of angiotensin and BK peptides and indicate that increased BK levels do not contribute to the actions of losartan. The absence of a reactive increase in endogenous kidney levels of Ang II indicates that this tissue is likely to be the most sensitive to AT1 receptor antagonism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Liu, Y. H., Yang, X. P., Sharov, V. G., Nass, O., Sabbah, H. N., Peterson, E., & Carretero, O. A. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119360 · Cited by 603
Vascular inflammation and the renin-angiotensin system
Brasier, A. R., Recinos, A., & Eledrisi, M. S. (2002) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000021412.56621.a2 · Cited by 586
The role of the renin-angiotensin system in the development of cardiovascular disease
Unger, T. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)02321-9 · Cited by 515
Recent Progress in Angiotensin II Type 2 Receptor Research in the Cardiovascular System
Horiuchi, M., Akishita, M., & Dzau, V. J. (1999) · Hypertension · doi:10.1161/01.hyp.33.2.613 · Cited by 473
Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonists
Taal, M. W., & Brenner, B. M. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00031.x · Cited by 439
Metadata
- Authors
- Campbell, D. J., Kladis, A., & Valentijn, A. J.
- Venue
- Journal of Cardiovascular Pharmacology
- Published
- 1995-08
- Volume
- 26
- Issue
- 2
- Pages
- 233-240
- ISSN
- 0160-2446 (ISSN-L)
- OpenAlex
- W1982525745
- Cited by
- 146
- References
- 0
- FWCI
- 7.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of Losartan on Angiotensin and Bradykinin Peptides and Angiotensin-Converting Enzyme. https://app.cochat.ai/papers/10.1097/00005344-199508000-00009
- The paper
- Campbell, D. J., Kladis, A., & Valentijn, A. J. (1995). Effects of Losartan on Angiotensin and Bradykinin Peptides and Angiotensin-Converting Enzyme. Journal of Cardiovascular Pharmacology. https://doi.org/10.1097/00005344-199508000-00009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.